medical technology (medtech)

The Series B round was co-led by venture capital (VC) firms, Lion X Ventures and Vickers Venture Partners.

Singapore's NDR Medical Technology is integrating AI and robotics to enable image-guided robotic healthcare procedures.

Impact Biomedical’s ownership in the suite is estimated to be at $1.32 billion.

The funds will be used to drive commercialization of its early gastric cancer detection system, SPECTRA IMDx, in Asia Pacific, and to expand the coverage of its cancer detection technology to other organs.

SINGAPORE (July 23): The Singapore government has earmarked the medical technology sector as one of the key growth drivers for the economy.

SINGAPORE (June 28): NRA Capital is reiterating its “overweight” recommendation on Trendlines Group with a fair value estimate of 22.5 cents.

SINGAPORE (Dec 12): Medical technology start-up Advent Access has raised $2.6 million in a pre-Series A financing round led by Accuron MedTech, Southeast Asia’s largest medical device company.

SINGAPORE (May 23): CIMB Research has issued an unrated report on Trendlines Group as an “intensely hands-on technology” incubator based in Israel, and as a stock that is currently trading at a discount to its global peers.

SINGAPORE (Oct 13): DBS Group Research has derived a fair value estimate of 43 cents for iX Biopharma in its preliminary assessment of what it deems a high-risk stock, with a view that investors should expect 0-20% potential returns from the stock over th

SINGAPORE (Sept 8): CIMB Research is initiating coverage of CEI Limited at “add” with a target price of $1.04, with expectations that its medical technology (medtech) and life science business will drive revenue growth of 5% over the FY17-18 forecast